IMIDomics

IMIDomics is a private, clinical-stage biotechnology company founded in 2007 and headquartered in San Francisco. It has built a unique, data-driven discovery and development platform centered on a proprietary biobank and deep clinical dataset from over 17,000 IMID patients and controls, collected over 17 years across a network of clinical centers. The company is using this platform to build a pipeline of first-in-class therapeutic candidates and companion biomarkers, aiming to improve outcomes for patients who do not respond to current therapies. Backed by experienced leadership and strategic partners, IMIDomics operates at the intersection of immunology, genetics, and bioinformatics.

Proprietary, integrated discovery platform built on a deeply phenotyped cohort of over 17,000 IMID patients and controls. It combines longitudinal clinical data (>10,000 variables), a large biobank (>1M specimens), and bioinformatics to identify novel therapeutic targets and biomarkers for patient stratification.

IMIDomics competes with large pharmaceutical companies (e.g., AbbVie, Johnson & Johnson, Pfizer) and numerous biotechs developing immunology therapies. Its differentiation lies in its proprietary, deep human data platform, which aims to de-risk target discovery and enable precision patient stratification, a competitive edge in a crowded field.